Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
Study Type
OBSERVATIONAL
Enrollment
150
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany
RECRUITINGChange in HFA-PEFF-Score
Heart Failure Association - Pre-test assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final aetiology; 2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements recommended; ≥ 5 points: HFpEF \[min. 0 points, max. 6 points\]
Time frame: 24 months
Development of HFpEF
Defined as ≥ 5 points in HFA-PEFF-Score Heart Failure Association - Pre-test assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final aetiology; 2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements recommended; ≥ 5 points: HFpEF \[min. 0 points, max. 6 points\]
Time frame: 24 months
Composite endpoint cardiovascular events
Cardiovascular hospitalisation or death
Time frame: 24 months
Change of individual parameters included in the HFA-PEFF-Score
Heart Failure Association - Pre-test assessment, Echocardiography and Natriuretic Peptide, Functional testing, Final aetiology; 2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements recommended; ≥ 5 points: HFpEF \[min. 0 points, max. 6 points\]
Time frame: 24 months
Change of NT-proBNP
Time frame: 24 months
Change of NYHA-class
Time frame: 24 months
Development or aggravation of albuminuria
Time frame: 24 months
Change of blood-creatinine
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.